Showing results (101-110 of 211) with videos related to

Sort By:
Pageof 22
Oncotarget|February 9, 2018
Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2Benjamin M Wahle, Eric T Hawley, Yongzheng He, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 1, 2020
A molecular basis for neurofibroma-associated skeletal manifestations in NF1Yun Ma, Andrea M Gross, Eva Dombi, et al.
Cancer Research|October 11, 2017
A Collaborative Model for Accelerating the Discovery and Translation of Cancer TherapiesOphélia Maertens, Mila E McCurrach, Benjamin S Braun, et al.
Nature Communications|May 10, 2012
Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA clusterMichael T Bocker, Francesca Tuorto, Günter Raddatz, et al.
Research Square|June 30, 2025
An induced pluripotent stem cell model of Schwann cell differentiation reveals NF2- related gene regulatory networksOlivia Lazaro, Sihong Li, William Carter, et al.
The Lancet. Oncology|October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trialKent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Blood|August 2, 2011
Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignanciesZhe Li, Xiaoqiang Cai, Chen-Leng Cai, et al.
Leukemia Research|May 11, 2011
Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76KZhenyun Yang, Mia Chen, Sarah A Sitarski, et al.
The Journal of Experimental Medicine|April 20, 2005
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistHal E Broxmeyer, Christie M Orschell, D Wade Clapp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Pageof 22